The omega-3 index: clinical utility for therapeutic intervention.
Red blood cell levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are a reflection of tissue levels and are determined by a complex interplay of metabolism and nutrition. Low levels of EPA+DHA in erythrocytes are associated with increased risk for sudden cardiac death. If levels of EPA+DHA in erythrocytes are determined using a strictly defined and standardized method, then the clinical significance of differing levels (previously defined in major research studies using this methodology) may be understood and applied in patient care. The Omega-3 Index, which is the EPA+DHA content of erythrocytes expressed as a percent of total identified fatty acids, was originally suggested as a marker of increased risk for death from coronary heart disease, but it can also be viewed as an actual risk factor, playing a pathophysiologic role in the disease. Optimal levels appear to be 8% or greater. At this stage of its development, the Omega-3 Index appears to fulfill many of the requirements for both a risk marker and a risk factor. Using the Omega-3 Index in the design of clinical studies might allow for a more efficient use of research resources.
Harris
William S
WS
Cardiovascular Health Research Center Sanford Research/USD, 2301 East 60th Street North, Sioux Falls, SD 57104-0589, USA. bill.harris@sanfordhealth.org
D015415:Biomarkers; D016757:Death, Sudden, Cardiac / Q000517:prevention & control; D004281:Docosahexaenoic Acids / Q000097:blood*; D015118:Eicosapentaenoic Acid / Q000097:blood*; D004912:Erythrocytes / Q000737:chemistry*; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage; D006304:Health Status; D006305:Health Status Indicators; D006801:Humans; D012307:Risk Factors; D014481:United States / Q000453:epidemiology
D015415:Biomarkers; D015525:Fatty Acids, Omega-3; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid
Curr Atheroscler Rep. 2009 Nov;11(6):411-7
19852881
Thromb Haemost. 2008 Oct;100(4):634-41
18841286
In Vivo. 2008 Jan-Feb;22(1):131-5
18396795
Am J Clin Nutr. 2010 Mar;91(3):528-34
20089730
JAMA. 2010 Jan 20;303(3):250-7
20085953
Prev Med. 2004 Jul;39(1):212-20
15208005
JAMA. 2009 Oct 21;302(15):1651-7
19843899
Proc R Soc Med. 1965 May;58:295-300
14283879
Circulation. 2002 Apr 23;105(16):1897-903
11997274
Lipids. 2008 Sep;43(9):805-11
18683001
Eur J Clin Pharmacol. 2004 May;60(3):183-90
15069592
N Engl J Med. 2002 Apr 11;346(15):1113-8
11948270
Atherosclerosis. 2008 Apr;197(2):821-8
17875307
Psychother Psychosom. 2009;78(2):125-7
19223688
Lancet. 2008 Oct 4;372(9645):1223-30
18757090
JAMA. 1995 Nov 1;274(17):1363-7
7563561
Clin Nephrol. 2009 May;71(5):508-13
19473610
Open Biomark J. 2008;1:1-6
19953197
Br J Nutr. 2009 Nov;102(9):1355-61
19505347
Circulation. 2009 May 5;119(17):2408-16
19364974
J Am Coll Cardiol. 2008 Aug 5;52(6):417-24
18672160
Lipids. 2010 Feb;45(2):137-44
20094809
Lancet. 2007 Mar 31;369(9567):1090-8
17398308
Resuscitation. 2008 Sep;78(3):258-64
18556107
Br J Nutr. 2010 Sep;104(5):729-36
20420756
J Lipid Res. 1997 Oct;38(10):2012-22
9374124
Am J Clin Nutr. 2008 Jun;87(6):1997S-2002S
18541601
Clin Biochem. 2010 Feb;43(3):338-40
19733159